Estelle Duprez

> Estelle DUPREZ > estelle.duprez@inserm.fr > French nationality > > 2 children > > **POSITION****:** > > Directeur de Recherche, deuxième classe, DR2 CNRS > > Team leader of the Team: Epigenetic factors in normal and malignant hematopoiesis, CRCM, IPC, U-1068 INSERM, UMR 7258 CNRS, Aix Marseille University. > > **EDUCATION****:** > 1990- Maîtrise de Biochimie. Paris VI. Mention assez bien > 1991- D.E.A. d'Endocrinologie et interactions cellulaires. Paris XI. Mention bien. > > 1995- Doctorat de l'université PARIS XI. Mention très honorable avec félicitations du jury > 2008-HDR de Aix-Marseille Université > > > **ACADEMIC APPOINTMENTS****:** > **1992-1995** PhD fellow, Unité INSERM U-301 Hôpital St Louis, PARIS. > Financial support: Bourse MRT, Bourse ARC. > **1996-1997** Postdoctoral fellow Paul Freemont Lab Imperial Cancer Research Fund, LondonFinancial support: Bourse individuelle "Capital Humain et Mobilité" de la CE. > > **1998**-Chargé de recherche (CR2) CNRS. INSERM U-496, Hopital Saint-Louis, Paris. > **1999-2002**-Détachement, Division of Hematology/ Oncology Harvard Institute of Medicine, Boston, USA, Dan Tenen Lab. > > **2003-2009**-Chargé de recherche (CR1) Mickael Sieweke lab. Centre d’Immunologie de Marseille Luminy. > > **2010-2011**- Chargé de recherche (CR1) CRCM IPC, U-1068 INSERM, UMR 7258 CNRS, Marseille. > > **2012**-**Now**- Directeur de recherche (DR2) Group leader: Epigenetic factors in normal and malignant hematopoiesis. CRCM IPC, U-1068 INSERM, UMR 7258 CNRS, Marseille > > **SCIENTIFIC PRODUCTION:** > > 52 Publications, 37 articles > 2100 citations, h index=22, > > 1 patent, WO2015169906-A1, 1 patent in preparation > > **Expertise/consulting, grant evaluation:** > > Expert for Leukaemia & Lymphoma Research Foundation LRF, England (2010-13), Cancéropôle Grandouest (2011), Celgene Corporation (2011), European Hematology Association (EHA) (2012-13; 2015), INSERM Contrat Interface Hospitalier (2012-13-2015), Scientific committee of LLC IDF (2013-16), Association Laurette Fugain (2014- ), Fondation de France (2016- ), Fondation Recherche Médical (2018-2021). Member of SFH. Member of the CHO organisation (2014-2017 ; treasurer 2016-17). > > Reviewer for : Journal of Experimental Medicine, PLoS Genetics, Cancer Research, Leukemia, Blood. > > **TEACHING/MENTORING:** > > Master Development & Immunity (3 days/year) and Master Human Pathology (2 day/year) Aix-Marseille-University. > > Member of M2 jury (2012; 2013; 2016 ;2019). Since 2008, Member of 9 PhD thesis/HDR jury. > > Mentor of 16 M1/M2 students, 2 Post-docs, Director of 7 PhD students, « Tuteur » of 2 PhD, > > **Invited conferences:** > > *-EHA, Stokholm, 2013,* Epigenetic profiling in AML > > *-HEMID, Milan, Juin 2012,* Polycomb Repressive Complexes in hematopoiesis > > -*17ème congrès de CHO, Les Embiez, Septembre 2011* > > -*International Florence Meeting in Hematology, Florence, 2010* > > *-EHA, Berlin, Juin 2009, PRC in APL* > > **SELECTED PUBLICATIONS :** > > Zidi, B., Vincent-FabertC., Pouyet, L., Seillier, M., Vandevelde, A., N’guessan, P., Guittard, G., Mancini, S., **Duprez, E****\***., Carrier, A**\***. TP53INP1 deficiency maintains murine B lymphopoiesis in aged bone marrow through redox controlled IL-7R/STAT5 signaling.(**PNAS*, in pres*s)**. \* Co-last and corresponding authorsKoubi, M., Poplineau M., Vernerey, J., N’Guyen L., El-Kaoutari, A., Garciaz, S., Tiberi, G., Maqbool MA, Andrau JC, Guillouf C., Saurin, A., **Duprez E**. Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity. **Nucleic Acids Res** doi: 10.1093/nar/gky080. (2018) PMID: 29425303Vincent-FabertC, PlatetN., Vandevelde, A., Poplineau M., Koubi, M., Finetti., P, Tiberi, G., Imbert, AM., Bertucci, F., **Duprez, E**. PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression 14;127:1881-5*,* **Blood** (2016).Kuhnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, **Duprez E**, Linch DC, Delwel R, Lowenberg B, Baldus CD, Solomon E, Burnett AK et al. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. **Blood** 125: 2985-94 (2015).Navarro, JM, Touzard, A, Pradel, L, Loosveld, M, Koubi, M, Fenouil, R, Le Noir, S, Ahmad Maqboo, M, Morgado, E,, Gregoire, C, Jaeger, S, Mamessier, E, Pignon, C, Hacein-Bey, S, Malissen, B Gut,M Gut,I, Dombret, H, Macintyre, E, Howes, S, Thrasher, A, Ifrah, N, Payet-Bornet, D, **Duprez, E\***, Andrau, JC\*, Asnafi, V\*, and Nadel,B\*. Site-& allele-specific de-silencing of polycomb repressive activity by insertional oncogenesis: a new recurrent mechanism of TAL1 activation in T-ALL. **Nat Commun**, 23;6: 6094 (2015). \* Equal contribution.Tiberi, G, Pekowska, A, Oudin, C, Ivey, A, Prebet, T, Koubi, M, Lembo, F, Mozziconacci, MJ, Bidaut, G, Autret, A, Chabannon, C, Grimwade, D, Vey, N, Spicuglia, S, Calmels, B, **Duprez, E**. PcG methylation of the *HIST1* cluster defines an epigenetic marker of Acute Myeloid Leukemia. **Leukemia***,* Dec 8. doi: 10.1038/leu.2014.339 (2015).Sarrazin S, Mossadegh-Keller, N Fukao T, Mossadegh-Keller, N, Aziz, A, Mourcin, F, Vanhille L, Kelly-Modis L, Kastern P, Chan S, **Duprez E**, Otto C, Sieweke M. MafB restricts m-CSF dependent Myeloid committment divsions of hematopoietic stem cells. **Cell**, 138: 300-13 (2009).Boukarabila H, Saurin A, Batsché E, Mossadegh N, VanLohuizen M, Otte A, Pradel J, Muchardt C, Sieweke M, **Duprez E**. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. **Genes Dev**, 23: 1195-1206 (2009).